Compare BRZE & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRZE | TLX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.3B |
| IPO Year | 2021 | N/A |
| Metric | BRZE | TLX |
|---|---|---|
| Price | $21.60 | $7.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 4 |
| Target Price | ★ $44.73 | $21.00 |
| AVG Volume (30 Days) | ★ 2.5M | 176.1K |
| Earning Date | 12-09-2025 | 01-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $693,412,000.00 | $664,225,558.00 |
| Revenue This Year | $25.69 | N/A |
| Revenue Next Year | $17.31 | N/A |
| P/E Ratio | ★ N/A | $181.75 |
| Revenue Growth | 22.95 | ★ 55.35 |
| 52 Week Low | $21.41 | $7.16 |
| 52 Week High | $47.60 | $30.36 |
| Indicator | BRZE | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 25.19 | 46.25 |
| Support Level | $22.66 | $7.16 |
| Resistance Level | $26.17 | $8.45 |
| Average True Range (ATR) | 1.60 | 0.22 |
| MACD | -0.50 | 0.11 |
| Stochastic Oscillator | 2.12 | 42.92 |
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates majority of its revenue from the United States.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.